Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +16% CER (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The performance reflected continued strong commercial momentum, driven by Vyepti® and Rexulti®, and was further shaped by the transition to a...
Everest Medicines Announces Interim Results for First Half of 2026
SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first half of 2026 along with a corporate update. Everest delivered strong growth and reached an important profitability milestone in the first...
GSK’s Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma
Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 Blenrep, a first-in-class anti-BCMA ADC, could transform treatment as early as first relapse where additional effective treatment options are needed,, SINGAPORE, Aug. 19, 2026 /PRNewswire/ -- GSK Singapore today announced that the...
Ping An Good Doctor Announces 2026 Interim Results
Corporate Health Management Business Grows Steadily; AI Healthcare Empowerment Drives Continued Profitability Improvement HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2026. During the period, the Company continued to improve its...
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the Company has been invited to participate in the...
CARsgen Therapeutics Announces 2026 Interim Results
SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights Cash and cash equivalents were around RMB1,400 million as of June 30, 2026. Cash and cash equivalents at the end...
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing. This acquisition transforms Yapan...
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately...
Rayence Breaks the Boundaries of Point-of-Care Imaging with the Launch of Integrated Portable X-ray Diagnostic Solutions ‘Anywhere-M’ and ‘Anywhere-V’
Integrated all-in-one workflow combining a portable X-ray generator, detector, and imaging software Powered by Rayence's proprietary SHINE denoising algorithm and military grade detector durability for emergency, disaster relief, and field diagnostics Cost effective, high performance solution designed to accelerate the expansion of telemedicine and mobile healthcare worldwide HWASEONG, South...
Frost & Sullivan: Juno Health Receives the 2026 North American Modular EHR Delivery Customer Value Leadership Recognition for Excellence in Cloud-Native EHR Innovation
The company stands out for delivering a scalable, cloud-native platform that enhances customer experience through flexible system ownership, operational efficiency, and cost-effective EHR modernization. SAN ANTONIO, Aug. 18, 2026 /PRNewswire/ -- This week we would like to congratulate Juno Health on earning Frost & Sullivan's 2026 North American Customer Value Leadership Recognition in the modular electronic health record (EHR)...
